USP Open Forum

Improving the Pharma Environmental Footprint

Virtual Meeting:
February 21, 2023 • 9:00–11:00 am EST
USP Open Forum

Improving the Pharma Environmental Footprint

Welcome!

Darcy Gentleman, Ph.D.

Senior Manager, Stakeholder Engagement
Welcome!

Agenda
- Opening remarks and USP focus
- Panel discussion
- Interactive discussion
- Closing thoughts

Idea generation, sharing knowledge of initiatives
Help us identify what questions need answers
Our mission

To improve global health through public standards and related programs that help ensure the quality, safety, and benefit of medicines and foods.
Collaborating to achieve our mission

USP Experts & Convention Members

Access to quality medicines

Global regulatory entities and other pharmacopeias

Scientific, healthcare stakeholder communities, including industry & academia
Global impact across the supply chain

USP-NF
9000+ standards

Dietary Supplement Compendium
1200+ standards

Suppliers

Manufacturers

Wholesale/Distributors

Pharmacies/Hospitals

Healthcare Providers

Patients

Broadly applicable analytical methods

350+ General Chapters
4900+ Monographs
3500+ Reference Standards
550+ Standards for biological products

Healthcare Quality and Safety 300+

- Nomenclature
- Compounding
- Model Guidelines
- Labeling
Disruptors shaping our evolution

- Digitalization, analytics & informatics
- Explosion of new therapies
- Complex, globalized supply chain
- New quality paradigms and technologies
- Climate change
- New ways of engaging scientists
- Medical information & knowledge
- Pandemic(s)
Standards, quality, and strategic design

- Quality by design
  - Standards to inform green/sustainable chemistry’s “benign by design” paradigm
- Efficiency
  - Public standards for scale and consistency
- Global perspective
Contribute ideas, respect all inputs
USP Open Forum

USP’s journey in reducing the pharma environmental footprint and future impact possibilities

Speaker:
Gabriel I. Giancaspro Ph.D.
Dist. Scientific Fellow/Compendial Policy Head, USP
USP Convention Resolution

Environmental Concerns (1995)
The USP is encouraged to initiate a program to protect the environment by adopting standards and analytical methods for pharmaceuticals, containers, and other articles that reduce the amount of reagents and materials used in pharmaceutical tests and assays that have the potential to cause harm to human health and the environment.

Source: Resolutions Adopted by the USP Convention, 1975 — 2015
Progress report in 2000

1995 Resolution on Environmental Concerns

- Reduction of dissolution medium acid normality
- Stimuli article in 1999 regarding disposal of drugs
- Publication on proper disposal of monograph formulations, given Resource Conservation and Recovery Act
- Elicit help from industry to revise tests using unusually large amounts of hazardous solvents
- Encourage use of lower-volume, higher efficiency separations via a chapter on capillary electrophoresis (CE)
- Reduce/eliminate environmentally objectionable solvents; also hydrogen sulfide
- Eliminate use of cats for testing Depressor Substance test
Global impact across the supply chain

- **USP-NF**
  - 9000+ standards

- **Dietary Supplement Compendium**
  - 1200+ standards

**Suppliers** → **Manufacturers** → **Wholesale/Distributors** → **Pharmacies/Hospitals** → **Healthcare Providers** → **Patients**

- **Broadly applicable analytical methods**
  - 350+ General Chapters
  - 4900+ Monographs
  - 3500+ Reference Standards
  - 550+ Standards for biological products

- **Healthcare Quality and Safety**
  - 300+
    - Nomenclature
    - Compounding
    - Model Guidelines
    - Labeling
Our journey continues

Communicating Impact & Aspirations

Stakeholder Input

Standards Prioritization Criteria

Green Scorecard

Improving the Pharma Environmental Footprint
USP has impacted the pharma environmental footprint mainly through two initiatives

<table>
<thead>
<tr>
<th>Modernization (official and unofficial)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>- Lowering / eliminating / substituting use of hazardous and toxic substances</td>
<td></td>
</tr>
<tr>
<td>- Incorporating new methods and technology that are more efficient and less wasteful</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Harmonization</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>- Improving alignment of quality standards with global pharmacopeias</td>
<td></td>
</tr>
<tr>
<td>- Moving towards a vision of prospective global convergence in recent times</td>
<td></td>
</tr>
</tbody>
</table>
USP Convention Resolution

*USP-NF Monograph Modernization (2015)*

USP will meet the needs of U.S. Food and Drug Administration (FDA), industry, and other stakeholders for modern monographs within *USP–NF*. USP will work to eliminate the existing backlog of monographs in need of modernization and proactively evaluate and update monographs to maintain their relevance given scientific advances and evolving manufacturing and regulatory approaches. USP will work with industry and FDA to explore new strategies for sharing analytical methods and specifications needed to modernize monographs.

Source: Resolutions Adopted by the USP Convention, 1975 — 2015
Modernization efforts

Lower/eliminate/substitute hazardous substances

- Benzene
  - Avoid (Class 1 solvent)
  - Decrease use in compendia by >80%

- Carbon tetrachloride
  - Class 1 solvent
  - Decrease use in compendia by >96%

- Amoxicillin
  - Strict limits on methylene chloride led supplier to explore enzymatic synthesis

- General Chapter <800>
  - Guidance on environmental quality & control in healthcare settings

Incorporate new methods and technologies to increase efficiency

- Chromatography
  - Column equivalencies
  - GC over LC
  - Reverse phase uses less of toxic solvents

- Explore emerging analytical methods
  - Pharmaceutical continuing manufacturing (PCM)
  - qNMR
  - Biotechnological methods
Pharmacopeial Discussion Group (PDG)

- What environmental or sustainability initiatives do your organizations have underway?
  - What opportunities to connect?

- What more can PDG do together to…..
  - **Inventory** the efforts and impact of PDG – and broadcast successes for others to adopt?
  - Bring environmental impact to the table as **criteria** for harmonization?
  - Incorporate green scorecard(s) and modernization priorities to **choose tests**?
  - Encourage **greater industry involvement**?
  - Other?
Encourage smaller volumes

General Notices and Chapter revisions

- Solution preparation
  - Recommend lower volumes with equivalent accuracy

- Chapter <31> Volumetric Apparatus
  - Companion informational <1331> Calibration and Verification of Volumetric Apparatus
  - Including micropipette considerations

- Chapter <41> Balances
  - Companion informational <1251> Weighing on an Analytical Balance
  - Including microbalance considerations
Other ongoing projects

- Evaluation of endotoxin recombinant factor C (rFC) for absence of pyrogen assurance
- Phasing out calomel electrodes (mercury [II] chloride)
- Replacing outdated wet chemistry methods using hazardous reagents
- Eliminating odor/taste aka “organoleptic” tests
- Continuing elimination of toxic solvents
- Analytical quality by design (AQbD) concepts to include reduction in waste generation
FY2022 Update:

“USP conducted studies aimed at optimizing dissolution testing using a reduced volume of dissolution media [to] reduce the environmental impact of dissolution testing while accelerating the process and expanding test applications … particle-induced velocimetry studies … along with computational fluid dynamics results, may provide further guidance … to improve analytical sensitivity while reducing the volume of solvents used.”

USP will explore the development of quality standards and other fit-for-purpose solutions to help stakeholders safeguard the quality of promising healthcare innovations that address patient and public health needs.
Pillars of interest = start of a potential USP framework

- Energy & emissions
- Waste
- Water stewardship
- Biodiversity conservation
- Employee (lab) health & safety

Good global citizens
Panel discussion

Moderator:

Darcy Gentleman, Ph.D.
Senior Stakeholder Engagement Manager
USP

Lina Bader, Ph.D.
Lead, Equity, Sustainability Policy, and Development
International Pharmaceutical Federation (FIP)

Isamir Martinez, Ph.D.
Scientific Alliances & Business Engagement Manager
Green Chemistry Institute,
American Chemical Society

Jane Weitzel, Ph.D.
Chair,
General Chapters – Measurement and Data Quality USP Expert Committee
Contact us!
sustainability@usp.org
Thank You

The standard of trust